VaxGen Gets OK to Test Anthrax Vaccine
- Share via
VaxGen Inc., which is developing vaccines for AIDS and smallpox, said it won Food and Drug Administration approval to begin testing a treatment to prevent anthrax.
Testing for the anthrax vaccine on about 100 volunteers will begin in June, a company spokesman said.
Shares of Brisbane, Calif.-based VaxGen rose 20 cents to $3.34 on Nasdaq.
The vaccine will be tested at Houston’s Baylor College of Medicine, Atlanta’s Emory University, Baltimore’s Johns Hopkins University and Saint Louis University Health Sciences Center.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
